Yi-Fang Chuang

Yi-Fang Chuang

Auto-generated profile, based on publicly available information

Yi-Fang Chuang

Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2018 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
YCYen-Ling Chiu
Yen-Ling Chiu
KSKai-Hsiang Shu
Kai-Hsiang Shu
FYFeng-Jung Yang
Feng-Jung Yang
TCTzu-Ying Chou
Tzu-Ying Chou
PCPing-Min Chen
Ping-Min Chen
YCYi-Fang Chuang
Yi-Fang Chuang
Patients with end-stage renal disease (ESRD) exhibit a premature aging phenotype of the immune system. Nevertheless, the etiology and impact of these changes in ESRD patients remain unknown. Compared to healthy individuals, ESRD patients exhibit accelerated immunosenescence in both T cell and monocyte compartments, characterized by a dramatic reduction in naïve CD4+ and CD8+ T cell numbers but increase in CD8+ TEMRA cell and proinflammatory monocyte numbers. Notably, within ESRD patients, aging-related immune changes positively correlated not only with increasing age but also with longer dialysis vintage. In multivariable-adjusted logistic regression models, the combination of high terminally differentiated CD8+ T cell level and high intermediate monocyte level, as a composite predictive immunophenotype, was independently associated with prevalent coronary artery disease as well as cardiovascular disease, after adjustment for age, sex, systemic inflammation and presence of diabetes. Levels of terminally differentiated CD8+ T cells also positively correlated with the level of uremic toxin p-cresyl sulfate. Aging-associated adaptive and innate immune changes are aggravated in ESRD and are associated with cardiovascular diseases. For the first time, our study demonstrates the potential link between immunosenescence in ESRD and duration of exposure to the uremic milieu.

25 May 2023 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
KFKang-Chen Fan
Kang-Chen Fan
CLChen-Ching Lin
Chen-Ching Lin
YLYi-Chien Liu
Yi-Chien Liu
YCYi-Ping Chao
Yi-Ping Chao
YLYen-Jun Lai
Yen-Jun Lai
YCYi-Fang Chuang
Yi-Fang Chuang
Introduction: The microbiota-gut-brain axis is implicated in Alzheimer’s disease. Gut microbiota alterations in mild cognitive impairment (MCI) are inconsistent and remain to be understood. This study aims to investigate the gut microbial composition associated with MCI, cognitive functions, and structural brain differences.Methods: A nested case-control study was conducted in a community-based prospective cohort where detailed cognitive functions and structural brain images were collected. Thirty-one individuals with MCI were matched to sixty-five cognitively normal controls by age strata, gender, and urban/rural area. Fecal samples were examined using 16S ribosomal RNA (rRNA) V3–V4 sequencing. Compositional differences between the two groups were identified and correlated with the cognitive functions and volumes/thickness of brain structures.Results: There was no significant difference in alpha and beta diversity between MCIs and cognitively normal older adults. However, the abundance of the genus Ruminococcus, Butyricimonas, and Oxalobacter decreased in MCI patients, while an increased abundance of nine other genera, such as Flavonifractor, were found in MCIs. Altered genera discriminated MCI patients well from controls (AUC = 84.0%) and were associated with attention and executive function.Conclusion: This study provides insights into the role of gut microbiota in the neurodegenerative process.

1 November 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
YCYi-Fang Chuang
Yi-Fang Chuang
JBJohn C.S. Breitner
John C.S. Breitner
YCYen-Ling Chiu
Yen-Ling Chiu
AKAra Khachaturian
Ara Khachaturian
Kathleen HaydenKathleen Hayden
Kathleen Hayden
PZPeter P. Zandi
Peter P. Zandi

1 September 2021 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
YCYi-Fang Chuang
Yi-Fang Chuang
YLYi-Chien Liu
Yi-Chien Liu
HTHsin-Yi Tseng
Hsin-Yi Tseng
PLPei-Xuan Lin
Pei-Xuan Lin
CLCheng-Yi Li
Cheng-Yi Li
YCYen-Ling Chiu
Yen-Ling Chiu
Taiwan is a rapidly aging society. The elderly with mild cognitive impairment (MCI) have increased risk of dementia, and this is a population-based report using standard neuropsychological tests and expert consensus diagnosis to assess the MCI prevalence and its associated factors in Taiwan. The Epidemiology of Mild Cognitive Impairment study in Taiwan (EMCIT) is a community-based, prospective cohort study. Independently-living individuals aged ≧60 years in a rural area (n = 122) and in an urban area (n = 348) of New Taipei City, Taiwan, completed detailed neuropsychological tests at the cohort baseline. Diagnosis of MCI was ascertained through expert consensus based on 2011 NIA-AA criteria. Of 470 participants recruited between 2017 and 2019 (mean age 71.2 ± 5.4 years), the prevalence of MCI was higher in the rural area than in the urban area (25.1% vs. 10.8%, p < 0.001) after standardized for age, gender, and level of education. Having lower education and having depression symptoms were consistently associated with increased risk of MCI in both urban and rural areas (p < 0.05). Being male and diabetes were additionally associated with MCI prevalence in urban areas. In this community-based prospective cohort study in Taiwan, the prevalence of MCI in the rural community was much higher than that in the urban community. Different strategies may be needed to targeted different types of communities.

1 June 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
YCYi-Fang Chuang
Yi-Fang Chuang
DEDana Eldreth
Dana Eldreth
KEKirk I. Erickson
Kirk I. Erickson
VVVijay Varma
Vijay Varma
GHGregory Harris
Gregory Harris
MCMichelle C. Carlson
Michelle C. Carlson

30 May 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KFKang-Chen Fan
Kang-Chen Fan
CLChen-Ching Lin
Chen-Ching Lin
YCYen-Ling Chiu
Yen-Ling Chiu
Seong-Ho KohSeong-Ho Koh
Seong-Ho Koh
YLYi-Chien Liu
Yi-Chien Liu
YCYi-Fang Chuang
Yi-Fang Chuang
Emerging evidence highlights the bidirectional communication between the gut microbiota and the brain, suggesting a potential role for gut dysbiosis in Alzheimer’s disease (AD) pathology and cognitive decline. Existing literature on gut microbiota lacks species-level insights. This study investigates gut microbiota alterations in mild cognitive impairment (MCI), focusing on their association with comprehensive AD biomarkers, including amyloid burden, tau pathology, neurodegeneration, and cognitive performance. We analyzed fecal samples from 119 individuals with MCI and 320 cognitively normal controls enrolled in the Taiwan Precision Medicine Initiative on Cognitive Impairment and Dementia cohort. Shotgun metagenomic sequencing was conducted with taxonomic profiling using MetaPhlAn4. Amyloid burden and plasma pTau181 were quantified via PET imaging and Simoa assays, respectively, while APOE genotyping was performed using TaqMan assays. Microbial diversity, differential abundance analysis, and correlation mapping with neuropsychological and neuroimaging measures were conducted to identify gut microbiota species signatures associated with MCI and AD biomarkers. We identified 59 key microbial species linked to MCI and AD biomarkers. Notably, species within the same genera, such as Bacteroides and Ruminococcus, showed opposing effects, while Akkermansia muciniphila correlated with reduced amyloid burden, suggesting a protective role. Functional profiling revealed microbial pathways contributing to energy metabolism and neuroinflammation, mediating the relationship between gut microbes and brain health. Co-occurrence network analyses demonstrated complex microbial interactions, indicating that the collective influence of gut microbiota on neurodegeneration. Our findings challenge genus-level microbiome analyses, revealing species-specific modulators of AD pathology. This study highlights gut microbial activity as a potential therapeutic target to mitigate cognitive decline and neurodegeneration.